New approaches in drug safety assessment based on information provided by doctors and patients in the register “PROFILE”

The aim to compare various sources of the pharmacotherapy safety information in the outpatient register.
Materials and methods. The original questionnaire included several questions for assessing information about patients’ knowledge of the concept of AEs of drug therapy, awareness of the possibility of drugs’ AEs, how often patients read the instructions for drugs and actions of patients in cases of AEs occurrence. Adverse events appearance were noted by the patients themselves in questionnaire and by doctors when completing the IRCs for the period from September 1. 2017 to May 31. 2018 are compared.
Results. Of the 162 patients who answered the questions in the original questionnaire, there were 80 women and 82 men. 112 patients were observed by doctors regularly (at least 1 time per year), 16 people visited doctors 1 time in 1–2 years, 14 people were with a doctor more than 2 years ago, in 18 patients information on the regularity of observation by doctors is not indicated were. According to the questionnaire, the majority of patients (145 (89.5 %)) were familiar with information about the possibility of developing side effects of drugs, and 125 (86.2 %) people received this information from their doctor, 19 (13.1 %) noted that the doctor did not inform them about this. Only 6 patients did not know anything about AE pharmacotherapy. As the questionnaire showed, most patients get acquainted with the instructions for the prescribed medications. Comparison of data from the IRCs and questionnaires revealed more frequent registration of AE by doctors; however, there was an incomplete coincidence of information about the presence of AE from different sources.
Conclusion. Using data from the retrospective-prospective registry with obtaining information about adverse events from doctors in combination with simultaneous patients questionare could get more complete information about safety of pharmacotherapy. At the same time solution to the problem of farmacotherapy safety lives in optimizing the doctor–patient relationship.

1. Saedder E.A., Lisby M., Nielsen L.P. et al. Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. Br J Clin Pharmacol 2015;80(4):808–17. DOI: 10.1111/bcp.12600.

2. Makary M.A., Daniel M. Medical error – the third leading cause of death in the US. BMJ 2016;353:2139. DOI: 10.1136/bmj.i2139.

3. Federal Law No. 61-FZ of 12.04.2010 “On the Circulation of Medicines”. As amended by Federal Laws No. 192-FZ of 27.07.2010, No. 271-FZ of 11.10.2010, No. 313-FZ of 11.29.2010. (In Russ.).

4. The Order of the Ministry of Health and Social Development of the Russian Federation No. 757n of August 26, 2010 “Approving the procedure for monitoring the safety of drugs for medical use, recording side effects, serious adverse reactions, unforeseen adverse reactions when using drugs for medical use”. (In Russ.).

5. Lepakhin V.K., Pereverzev A.P., Romanov B.K. Comparative evaluation of information on adverse reactions to medicines. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy 2015;(1):30–6. (In Russ.).

6. Lepakhin V.K., Sturov N.V., Astakhova A.V. Methods of identification and registration of adverse drug reactions during their widespread use. Trudnyy patsiyent = Difficult Patient 2008;(9):42–6. (In Russ.).

7. Drozdova L.Yu., Kutishenko N.P., Ginzburg M.L. Using Registers to Study Effectiveness and Safety of Drugs. The Clinician 2012;6(3–4): 4–9. (In Russ.).

8. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362(10):865–9. DOI: 10.1056/NEJMp0911494.

9. Lukina Yu.V., Dmitrieva N.A., Zakharova A.V. et al. Adverse event of drug therapy (the first results of the study according to the PROFILE outpatient register). Rational Pharmacotherapy in Cardiology 2016;12(3):306–13. (In Russ.).

10. Lukina Yu.V., Dmitrieva N.A., Kutishenko N.P. et al. The relationship and interinfluence of aspects of therapy safety and compliance in patients with cardiovascular diseases (by the data from outpatient registry “PROFILE”). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2018;17(5):72–8. (In Russ.).

11. Martsevich S.Yu., Lukina Yu.V., Kutishenko N.P. et al. Assessment of adherence to treatment and factors affecting it in patients with stable ischemic heart disease during therapy with nicorandil. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2017;13(6):776–86. (In Russ.).

12. Oganov R.G., Pogosova G.V., Koltunov I.E. et al. RELIPH – regular treatment and prevention – the key to improvement of situation with cardiovascular diseases in Russia: Results of Multicenter Study. Part I. Kardiologiya = Cardiology (In Russ.).

13. Zolnierek K.B., Dimatteo M.R. Physician сommunication and рatient adherence to treatment: a meta-analysis. Med Care 2009;47(8):826–34. DOI: 10.1097/MLR.0b013e31819a5acc.

14. Loke Y.K., Derry S., Aronson J.K. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004;57(5):616–21. DOI: 10.1111/j.0306-5251.2003.02055.x

15. Trotti A., Colevas A.D., Setser A., Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007;25(32):5121–7. DOI: 10.1200/JCO.2007.12.4784.